Cargando…

OnabotulinumtoxinA Displays Greater Biological Activity Compared to IncobotulinumtoxinA, Demonstrating Non-Interchangeability in Both In Vitro and In Vivo Assays

Differences in botulinum neurotoxin manufacturing, formulation, and potency evaluation can impact dose and biological activity, which ultimately affect duration of action. The potency of different labeled vials of incobotulinumtoxinA (Xeomin(®); 50 U, 100 U, or 200 U vials; incobotA) versus onabotul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rupp, David, Nicholson, Greg, Canty, David, Wang, Joanne, Rhéaume, Catherine, Le, Linh, Steward, Lance E., Washburn, Mark, Jacky, Birgitte P., Broide, Ron S., Philipp-Dormston, Wolfgang G., Brin, Mitchell F., Brideau-Andersen, Amy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354455/ https://www.ncbi.nlm.nih.gov/pubmed/32545832 http://dx.doi.org/10.3390/toxins12060393

Ejemplares similares

A Preclinical Study Comparing the Activity and Potency of OnabotulinumtoxinA and PrabotulinumtoxinA
por: Rupp, David C, et al.
Publicado: (2023)

Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin(®))
por: Dressler, Dirk, et al.
Publicado: (2013)

Comparison of neurotoxic potency between a novel chinbotulinumtoxinA with onabotulinumtoxinA, incobotulinumtoxinA and lanbotulinumtoxinA in rats
por: Feng, Ya, et al.
Publicado: (2017)

Real-World Dosing of OnabotulinumtoxinA and IncobotulinumtoxinA for Cervical Dystonia and Blepharospasm: Results from TRUDOSE and TRUDOSE II
por: Kent, Ruth, et al.
Publicado: (2021)

OnabotulinumtoxinA effects on trigeminal nociceptors
por: Moore, Ashley A, et al.
Publicado: (2023)

AbobotulinumtoxinA (Dysport(®)), OnabotulinumtoxinA (Botox(®)), and IncobotulinumtoxinA (Xeomin(®)) Neurotoxin Content and Potential Implications for Duration of Response in Patients
por: Field, Malgorzata, et al.
Publicado: (2018)

Real-World Six-Year National Cost-Minimization Analysis of IncobotulinumtoxinA and OnabotulinumtoxinA in the VA/DoD Healthcare Systems
por: Kazerooni, Rashid, et al.
Publicado: (2021)

Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study
por: Rappl, Thomas, et al.
Publicado: (2013)

OnabotulinumtoxinA affects cortical recovery period but not occurrence or propagation of cortical spreading depression in rats with compromised blood–brain barrier
por: Melo-Carrillo, Agustin, et al.
Publicado: (2021)

Correction: Field, M. et al. AbobotulinumtoxinA (Dysport(®)), OnabotulinumtoxinA (Botox(®)), and IncobotulinumtoxinA (Xeomin(®)) Neurotoxin Content and Potential Implications for Duration of Response in Patients
por: Field, Malgorzata, et al.
Publicado: (2019)

Botox (onabotulinumtoxinA) mechanism of action
por: Brin, Mitchell F., et al.
Publicado: (2023)

Profile of Xeomin(®) (incobotulinumtoxinA) for the treatment of blepharospasm
por: Park, Juwan, et al.
Publicado: (2011)

The pluripotential evolution and journey of Botox (onabotulinumtoxinA)
por: Brin, Mitchell F., et al.
Publicado: (2023)

Early development history of Botox (onabotulinumtoxinA)
por: Scott, Alan B., et al.
Publicado: (2023)

Pregnancy outcomes following exposure to onabotulinumtoxinA
por: Brin, Mitchell F., et al.
Publicado: (2015)

IncobotulinumtoxinA in aesthetics: Russian multidisciplinary expert consensus recommendations
por: Yutskovskaya, Yana, et al.
Publicado: (2015)

Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders
por: Jost, Wolfgang H, et al.
Publicado: (2015)

Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm
por: Truong, Daniel D., et al.
Publicado: (2013)

Safety and efficacy of incobotulinumtoxinA as a potential treatment for poststroke spasticity
por: Santamato, Andrea
Publicado: (2016)

Placebo-Controlled Clinical Trial of IncobotulinumtoxinA for Sialorrhea in Children: SIPEXI
por: Berweck, Steffen, et al.
Publicado: (2021)

Pooled Safety Analysis of IncobotulinumtoxinA in the Treatment of Neurological Disorders in Adults
por: Jost, Wolfgang H., et al.
Publicado: (2023)

OnabotulinumtoxinA Treatment for Moderate to Severe Forehead Lines: A Review
por: De Boulle, Koenraad, et al.
Publicado: (2020)

Quality of life in subjects with upper- and lower-limb spasticity treated with incobotulinumtoxinA
por: Fheodoroff, Klemens, et al.
Publicado: (2020)

Treatment of cervical dystonia with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Jankovic, Joseph, et al.
Publicado: (2023)

Treatment of strabismus and blepharospasm with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Scott, Alan B., et al.
Publicado: (2023)

Treatment of glabellar lines with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Carruthers, Jean, et al.
Publicado: (2023)

Treatment of chronic migraine with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Turkel, Catherine C., et al.
Publicado: (2023)

Preclinical assessment of onabotulinumtoxinA for the treatment of mild traumatic brain injury-related acute and persistent post-traumatic headache
por: Navratilova, Edita, et al.
Publicado: (2022)

Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia
por: Dressler, Dirk, et al.
Publicado: (2013)

Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines
por: Prager, Welf
Publicado: (2013)

SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea
por: Jost, Wolfgang H., et al.
Publicado: (2019)

Cost-Effectiveness of IncobotulinumtoxinA in the Treatment of Sialorrhea in Patients with Various Neurological Conditions
por: Makino, Koji, et al.
Publicado: (2020)

Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Lower Limb Spasticity in Japanese Subjects
por: Masakado, Yoshihisa, et al.
Publicado: (2022)

Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review
por: Burstein, Rami, et al.
Publicado: (2020)

Significantly lower antigenicity of incobotulinumtoxin than abo- or onabotulinumtoxin
por: Hefter, Harald, et al.
Publicado: (2022)

Pain Reduction in Adults with Limb Spasticity Following Treatment with IncobotulinumtoxinA: A Pooled Analysis
por: Wissel, Jörg, et al.
Publicado: (2021)

Cognitive effects of onabotulinumtoxinA in chronic migraine
por: Ho, Susan, et al.
Publicado: (2020)

A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia
por: Evidente, Virgilio Gerald H., et al.
Publicado: (2013)

Prospective evaluation of incobotulinumtoxinA in the management of the masseter using two different injection techniques
por: Nikolis, Andreas, et al.
Publicado: (2018)

Effects of Ultrasound-Guided Administration of Botulinum Toxin (IncobotulinumtoxinA) in Patients with Lateral Epicondylitis
por: Galván Ruiz, Antonio, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1tmh6j6pv3t6r2vp9fo7nsmcsi